Drugs / SCTV01C
last change Aug 2023 re-read 2 minutes ago

SCTV01C

Vaccine

Developed for
COVID-19
Investigated by
Sinocelltech Ltd.

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/23 trials
Phase 1/2 NCT05043311 Dec 2021 → Jun 2022 COVID-19 Sinocelltech Ltd. Unknown No outcome recorded
Phase 1/2 NCT05043285 Dec 2021 → Jun 2022 COVID-19 Sinocelltech Ltd. Unknown No outcome recorded
Phase 1/2 NCT05148091 Dec 2021 → Aug 2023 COVID-19 Sinocelltech Ltd. Completed No outcome recorded
Phase 24 trials
Phase 2 NCT05239975 Apr → Jul 2022 COVID-19 Sinocelltech Ltd. Withdrawn No outcome recorded
Phase 2 NCT05308602 Apr → Aug 2022 COVID-19 Sinocelltech Ltd. Withdrawn No outcome recorded
Phase 2 NCT05239806 Apr → Aug 2022 COVID-19 Sinocelltech Ltd. Unknown No outcome recorded
Phase 2 NCT05238454 Mar → Jul 2022 COVID-19 Sinocelltech Ltd. Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT05323461 May → Oct 2022 COVID-19 Sinocelltech Ltd. Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as SCTV01C ClinicalTrials.gov intervention name — accepted as the source's own label NCT05323461
7

NCT05308602

NCT05239806

NCT05239975

NCT05148091

NCT05043285

NCT05043311

NCT05238454

Modality Vaccine “a novel bivalent protein vaccinePMID 36470077 Dec 2022
Route Intramuscular intramuscular injection” NCT05043285